{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:05:54Z","timestamp":1790604354290,"version":"4.1.0"},"reference-count":44,"publisher":"Gobierno de Navarra","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An Sist Sanit Navar"],"published-print":{"date-parts":[[2021,8,20]]},"DOI":"10.23938\/assn.0965","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T13:23:08Z","timestamp":1624627388000},"page":"261-273","source":"Crossref","is-referenced-by-count":20,"title":["Safety considerations during prescription of non-steroidal anti-inflammatory drugs (NSAIDs), through a review of systematic reviews"],"prefix":"10.23938","volume":"44","member":"10024","reference":[{"key":"ref0","unstructured":"1. LOZA E. AINEs en la pr\u00e1ctica cl\u00ednica: lo que hay que saber. Inf Ter Sist Nac Salud 2011; 35: 88-95."},{"key":"ref1","unstructured":"2. Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de Espa\u00f1a. Utilizaci\u00f3n de medicamentos antiinflama-torios no esteroideos en Espa\u00f1a durante el periodo 2013-2016. Informe de utilizaci\u00f3n de medicamentos U\/AIN\/V1\/11\/09\/2017. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/observatorio\/docs\/antiinflamatorios-AINEs-periodo-2013-2016.pdf"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. WELSBY PD. WHO analgesic ladder. Treasure Island: StatPearls Publishing 2008; 284.","DOI":"10.1177\/14782715200838030211"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. BREIVIK H, COLLETT B, VENTAFRIDDA V, COHEN R, GALLACHER D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333. https:\/\/doi.org\/10.1016\/j.ejpain.2005.06.009","DOI":"10.1016\/j.ejpain.2005.06.009"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. UBEDA A, FERR\u00c1NDIZ ML, MAICAS N, GOMEZ C, BONET M, PERIS JE. [Potentially inappropriate prescribing in institu-tionalised older patients in Spain: the STOPP-START criteria compared with the Beers criteria]. Pharm Pract 2012; 10: 83-91 https:\/\/doi.org\/10.4321\/s1886-36552012000200004","DOI":"10.4321\/S1886-36552012000200004"},{"key":"ref5","unstructured":"6. RISSER A, DONOVAN D, HEINTZMAN J, PAGE T. NSAID prescribing precautions. Am Fam Physician 2009; 80: 1371-1378."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. SMITH V, DEVANE D, BEGLEY CM, CLARKE M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol 2011; 11: 1-6. https:\/\/doi.org\/10.1186\/1471-2288-11-15","DOI":"10.1186\/1471-2288-11-15"},{"key":"ref7","unstructured":"8. Ministerio de Sanidad. Gobierno de Espa\u00f1a. Red Espa\u00f1ola de Agencias de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias y Prestaciones del Sistema Nacional de Salud. https:\/\/redets.sanidad.gob.es\/"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. BOUGIOUKAS KI, BOURAS E, APOSTOLIDOU-KIOUTI F, KOKKALI S, ARVANITIDOU M, HAIDICH A-B. Reporting guide-lines on how to write a complete and transparent abstract for overviews of systematic reviews of health care inter-ventions. J Clin Epidemiol 2019; 106: 70-79. https:\/\/doi.org\/10.1016\/j.jclinepi.2018.10.005","DOI":"10.1016\/j.jclinepi.2018.10.005"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. SHEA BJ, REEVES BC, WELLS G, THUKU M, HAMEL C, MORAN J et al. AMSTAR 2: A critical appraisal tool for sys-tematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017; 358. https:\/\/doi.org\/10.1136\/bmj.j4008","DOI":"10.1136\/bmj.j4008"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. SRIUTTHA P, SIRICHANCHUEN B, PERMSUWAN U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systemat-ic review of randomized controlled trials. Int J Hepatol 2018. https:\/\/doi.org\/10.1155\/2018\/5253623","DOI":"10.1155\/2018\/5253623"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. NDERITU P, DOOS L, JONES PW, DAVIES SJ, KADAM UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: A systematic review. Fam Pract 2013; 30: 247-255. https:\/\/doi.org\/10.1093\/fampra\/cms086","DOI":"10.1093\/fampra\/cms086"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. ZHANG X, DONNAN PT, BELL S, GUTHRIE B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and me-ta-analysis. BMC Nephrol 2017; 18: 256. https:\/\/doi.org\/10.1186\/s12882-017-0673-8","DOI":"10.1186\/s12882-017-0673-8"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. ASGHAR W, JAMALI F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a sys-tematic review. Inflammopharmacology 2014; 23: 1-16. https:\/\/doi.org\/10.1007\/s10787-014-0225-9","DOI":"10.1007\/s10787-014-0225-9"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. YAXLEY J, LITFIN T. Non-steroidal anti-inflammatories and the development of analgesic nephropathy: a systematic review. Ren Fail 2016; 38: 1328-1334. https:\/\/doi.org\/10.1080\/0886022x.2016.1216708","DOI":"10.1080\/0886022X.2016.1216708"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. VILLA J, CANO A, FRANCO D, MONSALVE M, HINCAPI\u00c9 J, AMARILES P. [Clinical relevance of drug interactions be-tween nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives]. Aten Primaria 2014; 46: 464-474 https:\/\/doi.org\/10.1016\/j.aprim.2013.11.010","DOI":"10.1016\/j.aprim.2013.11.010"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. UNGPRASERT P, SRIVALI N, THONGPRAYOON C. Nonsteroidal anti-inflammatory drugs and risk of incident heart failure: a systematic review and meta-analysis of observational studies. Clin Cardiol 2016; 39: 111-118. https:\/\/doi.org\/10.1002\/clc.22502","DOI":"10.1002\/clc.22502"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. LIU G, YAN YP, ZHENG XX, XU YL, LU J, HUI RT et al. Meta-analysis of nonsteroidal anti-inflammatory drug use and risk of atrial fibrillation. Am J Cardiol 2014; 114: 1523-1529. https:\/\/doi.org\/10.1016\/j.amjcard.2014.08.015","DOI":"10.1016\/j.amjcard.2014.08.015"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. SESHASAI SRK, WIJESURIYA S, SIVAKUMARAN R, NETHERCOTT S, ERQOU S, SATTAR N et al. Effect of aspirin on vas-cular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-216. https:\/\/doi.org\/10.1001\/archinternmed.2011.628","DOI":"10.1001\/archinternmed.2011.628"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. WHITLOCK EP, BURDA BU, WILLIAMS SB, GUIRGUIS-BLAKE JM, EVANS C V. Bleeding risks with aspirin use for pri-mary prevention in adults: a systematic review for the U.S. preventive services task force. Ann Intern Med 2016; 164: 826-835. https:\/\/doi.org\/10.7326\/m15-2112","DOI":"10.7326\/M15-2112"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. BOULAKH L, GISLASON GH. Treatment with non-steroidal anti-inflammatory drugs in patients after myocardial in-farction - a systematic review. Expert Opin Pharmacother 2016; 17: 1387-1394. https:\/\/doi.org\/10.1080\/14656566.2016.1186648","DOI":"10.1080\/14656566.2016.1186648"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. UNGPRASERT P, SRIVALI N, KITTANAMONGKOLCHAI W. Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis. Eur J Intern Med 2015; 26: 685-690. https:\/\/doi.org\/10.1016\/j.ejim.2015.09.012","DOI":"10.1016\/j.ejim.2015.09.012"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. GARC\u00cdA RODR\u00cdGUEZ LA, GONZ\u00c1LEZ-P\u00c9REZ A, BUENO H, HWA J. NSAID use selectively increases the risk of non-fatal myocardial infarction: A systematic review of randomised trials and observational studies. PLoS One 2011; 6: e16780. https:\/\/doi.org\/10.1371\/journal.pone.0016780","DOI":"10.1371\/journal.pone.0016780"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. SALVO F, FOURRIER-R\u00c9GLAT A, BAZIN F, ROBINSON P, RIERA-GUARDIA N, HAAG M et al. Cardiovascular and gastro-intestinal safety of NSAIDs: A systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011; 89: 855-866. https:\/\/doi.org\/10.1038\/clpt.2011.45","DOI":"10.1038\/clpt.2011.45"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. SCOTT PA, KINGSLEY GH, SCOTT DL. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail 2008; 10: 1102-1107. https:\/\/doi.org\/10.1016\/j.ejheart.2008.07.013","DOI":"10.1016\/j.ejheart.2008.07.013"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. VARAS-LORENZO C, RIERA-GUARDIA N, CALINGAERT B, CASTELLSAGUE J, SALVO F, NICOTRA F et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepi-demiol Drug Saf 2013; 22: 559-570. https:\/\/doi.org\/10.1002\/pds.3437","DOI":"10.1002\/pds.3437"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. MCGETTIGAN P, HENRY D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med 2011; 8. https:\/\/doi.org\/10.1371\/journal.pmed.1001098","DOI":"10.1371\/journal.pmed.1001098"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. MACKENZIE IS, WEI L, MACDONALD TM. Cardiovascular safety of lumiracoxib: A meta-analysis of randomised controlled trials in patients with osteoarthritis. Eur J Clin Pharmacol 2013; 69: 133-141. https:\/\/doi.org\/10.1007\/s00228-012-1335-1","DOI":"10.1007\/s00228-012-1335-1"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. MAJOR RW, OOZEERALLY I, DAWSON S, RIDDLESTON H, GRAY LJ, BRUNSKILL NJ. Aspirin and cardiovascular prima-ry prevention in non-endstage chronic kidney disease: A meta-analysis. Atherosclerosis 2016; 251: 177-182. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.06.013","DOI":"10.1016\/j.atherosclerosis.2016.06.013"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. LUNI FK, RIAZ H, KHAN AR, RIAZ T, HUSNAIN M, RIAZ I BIN et al. Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis. Catheter Cardiovasc Interv 2017; 89: 1168-1175. https:\/\/doi.org\/10.1002\/ccd.26807","DOI":"10.1002\/ccd.26807"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. LEE M, SAVER JL, HONG KS, WU HC, OVBIAGELE B. Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm a meta-analysis. Circ Hear Fail 2013; 6: 287-292. https:\/\/doi.org\/10.1161\/circheartfailure.112.971697","DOI":"10.1161\/CIRCHEARTFAILURE.112.971697"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. BEM D, LORDKIPANIDZ\u00c9 M, HODGKINSON J, STEVENS S, BAYLISS S, MOORE D et al. The effects of different aspirin dosing frequencies and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: a systematic review. Clin Pharmacol Ther 2016; 100: 500-512. https:\/\/doi.org\/10.1002\/cpt.438","DOI":"10.1002\/cpt.438"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. LANAS A, BENITO P, ALONSO J, HERN\u00c1NDEZ-CRUZ B, BAR\u00d3N-ESQUIVIAS G, PEREZ-A\u00cdSA \u00c1 et al. [Safe prescription recommendations for non steroidal anti-inflammatory drugs: Consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)]. Reumatol Clin 2014; 10: 68-84. https:\/\/doi.org\/10.1016\/j.reuma.2013.10.004","DOI":"10.1016\/j.reuma.2013.10.004"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. GISLASON GH, K\u00d8BER L, SCHJERNING OLSEN A-M, LOCK HANSEN M, TORP-PEDERSEN C, FOSB\u00d8L EL et al. NSAIDs are associated with increased risk of atrial fibrillation in patients with prior myocardial infarction: a nationwide study. Eur Hear J Cardiovasc Pharmacother 2015; 1: 107-114. https:\/\/doi.org\/10.1093\/ehjcvp\/pvv004","DOI":"10.1093\/ehjcvp\/pvv004"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. JONES R, RUBIN G, BERENBAUM F, SCHEIMAN J. Gastrointestinal and cardiovascular risks of nonsteroidal an-ti-inflammatory drugs. Am J Med 2008; 121: 464-474. https:\/\/doi.org\/10.1016\/j.amjmed.2008.01.045","DOI":"10.1016\/j.amjmed.2008.01.045"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. POPE JE, ANDERSON JJ, FELSON DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477-484. https:\/\/doi.org\/10.1001\/archinte.1993.00410040045007","DOI":"10.1001\/archinte.1993.00410040045007"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. JOHNSON AG, NGUYEN TV, DAY RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A me-ta-analysis. Ann Intern Med 1994; 121: 289. https:\/\/doi.org\/10.7326\/0003-4819-121-4-199408150-00011","DOI":"10.7326\/0003-4819-121-4-199408150-00011"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. TRELLE S, REICHENBACH S, WANDEL S, HILDEBRAND P, TSCHANNEN B, VILLIGER PM et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 154. https:\/\/doi.org\/10.1136\/bmj.c7086","DOI":"10.1136\/bmj.c7086"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. HOWELL M, WALKER RC, HOWARD K. Cost Effectiveness of dialysis modalities: a systematic review of economic evaluations. Appl Health Econ Health Policy 2019. https:\/\/doi.org\/10.1007\/s40258-018-00455-2","DOI":"10.1007\/s40258-018-00455-2"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. PIEPER D, BUECHTER R, JERINIC P, EIKERMANN M. Overviews of reviews often have limited rigor: a systematic re-view. J Clin Epidemiol 2012; 65: 1267-1273. https:\/\/doi.org\/10.1016\/j.jclinepi.2012.06.015","DOI":"10.1016\/j.jclinepi.2012.06.015"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. SOSTRES C, LANAS \u00c1. [Appropriate prescription, adherence and safety of non-steroidal anti-inflammatory drugs]. Med Clin 2016; 146: 267-272. https:\/\/doi.org\/10.1016\/j.medcli.2015.09.022","DOI":"10.1016\/j.medcli.2015.09.022"},{"key":"ref41","unstructured":"42. BRODY H. Promoting conversations between providers and patients. ABIM Foundation. Choosing Wisely 2012. http:\/\/www.choosingwisely.org\/"},{"key":"ref42","unstructured":"43. National Institute for Health and Care Excellence. NICE \"do not do\" recommendations. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-guidelines"},{"key":"ref43","unstructured":"44. Ministerio de Sanidad, Consumo y Bienestar Social. Compromiso por la calidad de las Sociedades Cient\u00edficas en Espa\u00f1a. Implementaci\u00f3n de las recomendaciones de \"No Hacer\". 2018. https:\/\/www.mscbs.gob.es\/organizacion\/sns\/planCalidadSNS\/cal_sscc.htm"}],"container-title":["Anales del Sistema Sanitario de Navarra"],"original-title":[],"link":[{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/83166\/66541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T02:20:55Z","timestamp":1749003655000},"score":1,"resource":{"primary":{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/83166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.23938\/assn.0965","relation":{},"ISSN":["1137-6627"],"issn-type":[{"value":"1137-6627","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}